Merck Gets FDA Expanded OK for Prevymis in Kidney Transplant Patients
06 June 2023 - 9:47PM
Dow Jones News
By Colin Kellaher
Merck & Co. on Tuesday said the U.S. Food and Drug
Administration approved the expanded use of its antiviral agent
Prevymis against a common viral infection experienced by transplant
recipients.
The Kenilworth, N.J., drugmaker said the approval covers
Prevymis for the prevention of cytomegalovirus disease in adult
kidney transplant recipients at high risk.
Prevymis, which the FDA first approved in 2017, generated
revenue of $428 million last year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 06, 2023 07:32 ET (11:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024